Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing programs include SLS-004, SLS-006, and SLS-007.
- Revenue in USD (TTM)808.00k
- Net income in USD-72.96m
- Incorporated1987
- Employees16.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicinova Inc | 0.00 | -13.60m | 106.44m | 13.00 | -- | 1.57 | -- | -- | -0.2773 | -0.2773 | 0.00 | 1.38 | 0.00 | -- | -- | 0.00 | -17.51 | -17.37 | -18.18 | -17.97 | -- | -- | -- | -1,626.60 | -- | -- | 0.00 | -- | -100.00 | -- | -38.83 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.09m | 107.62m | 4.00 | -- | 3.87 | -- | -- | -0.3958 | -0.3958 | 0.00 | 0.8987 | 0.00 | -- | -- | 0.00 | -38.54 | -80.77 | -39.42 | -85.60 | -- | -- | -- | -3,362.83 | -- | -- | 0.00 | -- | -100.00 | -- | -4.95 | -- | -- | -- |
| Eyenovia Inc | 0.00 | -26.41m | 107.93m | 41.00 | -- | 6.82 | -- | -- | -0.7485 | -0.7485 | 0.00 | 0.4162 | 0.00 | -- | -- | 0.00 | -76.01 | -83.43 | -97.43 | -122.63 | -- | -- | -- | -618.56 | -- | -16.75 | 0.3726 | -- | -100.00 | -- | -119.21 | -- | 121.09 | -- |
| Veru Inc | 21.28m | -138.85m | 108.87m | 233.00 | -- | 6.03 | -- | 5.11 | -1.73 | -1.73 | 0.2646 | 0.2024 | 0.1751 | 1.27 | 3.45 | 91,350.17 | -114.25 | -30.72 | -152.05 | -37.95 | 58.11 | 73.21 | -652.37 | -68.79 | 0.9074 | -- | 0.4099 | -- | -35.76 | 23.58 | -1,232.97 | -- | 40.58 | -- |
| Seelos Therapeutics Inc | 808.00k | -72.96m | 109.63m | 16.00 | -- | -- | -- | 135.68 | -0.6779 | -0.6779 | 0.0075 | -0.1696 | 0.0171 | -- | -- | 53,866.67 | -154.69 | -168.03 | -324.26 | -259.48 | -- | -- | -9,030.20 | -56,910.13 | -- | -- | -- | -- | -- | -- | -11.33 | -- | -- | -- |
| Moolec Science SA | 0.00 | -602.87k | 109.68m | -- | -- | 2.12 | -- | -- | -0.0339 | -0.0339 | 0.00 | 1.38 | 0.00 | -- | -- | -- | -0.7234 | -- | -0.7463 | -- | -- | -- | -- | -- | -- | -- | 0.0554 | -- | -- | -- | -579.78 | -- | -- | -- |
| Decibel Therapeutics Inc | 0.00 | -62.29m | 109.82m | 68.00 | -- | 1.57 | -- | -- | -2.49 | -2.49 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -43.83 | -- | -51.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.39 | -- | -- | -- |
| Alaunos Therapeutics Inc | 2.92m | -37.99m | 112.78m | 34.00 | -- | 3.82 | -- | 38.60 | -0.1703 | -0.1703 | 0.0131 | 0.1226 | 0.0437 | -- | -- | 85,941.18 | -56.86 | -69.23 | -79.70 | -81.33 | -- | -- | -1,300.14 | -10,599.25 | -- | -10.78 | 0.2713 | -- | 634.17 | -14.48 | 52.09 | -- | -21.77 | -- |
| Nektar Therapeutics | 88.83m | -414.82m | 113.92m | 216.00 | -- | 0.473 | -- | 1.28 | -2.21 | -2.21 | 0.4728 | 1.27 | 0.112 | 1.31 | 5.35 | 411,236.10 | -52.32 | -14.82 | -58.40 | -16.37 | 73.68 | 93.24 | -467.00 | -66.22 | 7.86 | -9.28 | 0.00 | -- | -9.67 | -21.44 | 29.71 | -- | -10.12 | -- |
| CytomX Therapeutics Inc | 59.53m | -78.74m | 114.10m | 116.00 | -- | -- | -- | 1.92 | -1.20 | -1.20 | 0.9026 | -1.31 | 0.224 | -- | 56.53 | 513,146.60 | -29.63 | -23.82 | -56.77 | -32.06 | -- | -- | -132.29 | -141.28 | -- | -- | -- | -- | 42.48 | -5.79 | 14.29 | -- | 2.22 | -- |
| Pardes Biosciences Inc | 0.00 | -93.00m | 114.18m | 57.00 | -- | 0.6735 | -- | -- | -1.58 | -1.58 | 0.00 | 2.75 | 0.00 | -- | -- | 0.00 | -43.13 | -- | -45.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.88 | -- | -- | -- |
| Cidara Therapeutics Inc | 83.17m | -8.99m | 114.33m | 73.00 | -- | 4.26 | -- | 1.37 | -0.1647 | -0.1647 | 1.00 | 0.2981 | 1.21 | -- | 4.81 | 1,139,301.00 | -12.13 | -70.43 | -23.99 | -120.17 | -- | -- | -9.99 | -166.50 | -- | -- | 0.00 | -- | 29.69 | -- | 29.83 | -- | -17.35 | -- |
| AN2 Therapeutics Inc | 0.00 | -48.62m | 114.81m | 35.00 | -- | 1.39 | -- | -- | -2.51 | -2.51 | 0.00 | 4.25 | 0.00 | -- | -- | 0.00 | -45.96 | -- | -49.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -52.46 | -- | -- | -- |
Data as of Jun 07 2023. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
15.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tontine Associates LLCas of 31 Mar 2023 | 5.07m | 4.22% |
| The Vanguard Group, Inc.as of 31 Mar 2023 | 4.98m | 4.15% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 1.65m | 1.37% |
| Horizons ETFs Management (Canada), Inc.as of 31 Mar 2023 | 1.44m | 1.20% |
| Geode Capital Management LLCas of 31 Mar 2023 | 1.14m | 0.95% |
| Uniplan Investment Counsel, Inc.as of 31 Mar 2023 | 1.13m | 0.94% |
| Wealth Effects LLCas of 31 Mar 2023 | 956.05k | 0.80% |
| MAI Capital Management LLCas of 31 Mar 2023 | 927.42k | 0.77% |
| Modera Wealth Management LLCas of 31 Mar 2023 | 871.51k | 0.73% |
| Millennium Management LLCas of 31 Mar 2023 | 624.86k | 0.52% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
